News|Articles|October 2, 2025

FDA news recap in benign urology for Q3 2025

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

Take a look back at the notable regulatory decisions in benign urology between July and September.

The landscape in benign urology continues to see steady progress. In Q3 of 2025, this progress was marked by key priority review designations, which set the stage for decisions in hypoactive sexual desire disorder and uncomplicated gonorrhea in the months ahead. Q3 also welcomed approvals for novel devices for urge urinary incontinence and cystoscopy, highlighting the continued technologic advances that are transforming care.